Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-I, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System

 


A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-I, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System


Trial Focus

Leukemia/Myelodysplasia

Objective

         This is a clinical trial of rigosertib that will be administered by mouth which is investigational.

IRB Protocol #

13-2064

Trial Status

Archived

Principle Investigator

DAN POLLYEA

Sponsor

Onconova

Contact

DEREK SCHATZ at (720)848-0628 or DEREK.SCHATZ@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to 48 weeks. A follow up period will consist of physician contact and clinic visit. // Eligibility criteria include but are not limited to 18 years or older with myelodysplastic syndrome (MDS).Eligibility criteria include but are not limited to 18 years or older with myelodysplastic syndrome (MDS).